Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
November 20, 2023 08:00 ET
|
Tempest Therapeutics
BRISBANE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted...
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
November 08, 2023 17:17 ET
|
Tempest Therapeutics
TPST-1120 demonstrates superiority compared to standard of care across multiple study endpoints in randomized first-line HCC studyNew capital strengthens balance sheet and extends cash runway into...
Tempest Adopts Limited Duration Stockholder Rights Plan
October 11, 2023 08:01 ET
|
Tempest Therapeutics
BRISBANE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted...
Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study
October 11, 2023 08:00 ET
|
Tempest Therapeutics
New data package reveals improvements in multiple categories for TPST-1120 combined with atezolizumab + bevacizumab versus standard of care atezolizumab + bevacizumab in a global Phase 1b/2...
Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
October 10, 2023 16:05 ET
|
Tempest Therapeutics
BRISBANE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted...
Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
September 19, 2023 08:00 ET
|
Tempest Therapeutics
BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted...
Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 08:00 ET
|
Tempest Therapeutics
BRISBANE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted...
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 16:13 ET
|
Tempest Therapeutics
BRISBANE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted...
Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together
July 19, 2023 08:00 ET
|
Tempest Therapeutics
In vitro and in vivo data show significant increased potency by blocking prostaglandin PGE2 signaling through both EP2 and EP4 receptors compared to celecoxib or single EP4 antagonists TPST-1495...
Tempest to Present at the Jefferies Global Healthcare Conference
May 31, 2023 16:05 ET
|
Tempest Therapeutics
BRISBANE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and...